Drugs for Parkinsonism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 95)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Varenicline |
Approved, Investigational |
Phase 4 |
|
249296-44-4 |
5310966 |
Synonyms:
6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)benzazepine
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)(3)benzazepine
Champix
Champix®|Chantix®|compound 9a [PMID: 16171993]|CP 526555
Chantix
CP-526,555
|
CP-526555
Tartrate, varenicline
Vareniclina
VARENICLINE
Varenicline tartrate
Vareniclinum
|
|
2 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
3 |
|
Risperidone |
Approved, Investigational |
Phase 4 |
|
106266-06-2 |
5073 |
Synonyms:
Belivon
Buspirone
Consta, risperdal
LY03004
LY-03004
N05AX08
Okedi®|R-64-766|R-64766|Risperdal®
PERSERIS KIT
R-64,766
R-64766
R-64-766
RCN3028
RCN-3028
Rispen
Risperdal
Risperdal consta
RISPERDAL CONSTA LONG ACTING
|
RISPERDAL M
Risperdal m-tab
RISPERDAL QUICKLET
RISPERDONE
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Rispéridone
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
Sequinan
Spiron
|
|
4 |
|
Olanzapine |
Approved, Investigational |
Phase 4 |
|
132539-06-1 |
135398745 4585 |
Synonyms:
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-B][1,5]BENZODIAZEPINE
ARKOLAMYL
Lanzac
LY170053
LY-170053
LY-170053|Zyprexa®
Olansek
OLANZAPIN
Olanzapina
|
OLANZAPINE
Olanzapine pamoate
Olanzapinum
Symbyax
ZALASTA
Zolafren
Zydis
Zyprexa
Zyprexa intramuscular
Zyprexa zydis
|
|
5 |
|
Amantadine |
Approved |
Phase 4 |
|
768-94-5 |
2130 |
Synonyms:
1 Aminoadamantane
1-Adamantanamine
1-Adamantylamine
1-Aminoadamantane
AbZ brand OF amantadine hydrochloride
Adamantamine
Adamantanamine
Adamantylamine
Adekin
ADS-5102|Gocovri®|Symadine®|Symmetrel®
AL, amantadin
Aliud brand OF amantadine sulfate
Alliance brand OF amantadine hydrochloride
Aman
Amanta
Amanta hci azu
Amanta sulfate azu
Amantadin al
Amantadin azu
Amantadin neuraxpharm
Amantadin ratiopharm
Amantadin stada
Amantadina
Amantadina juventus
Amantadina llorente
AMANTADINE
Amantadine base
Amantadine HCL
Amantadine hydrochloride
Amantadine sulfate
Amantadinneuraxpharm
Amantadin-neuraxpharm
Amantadinratiopharm
Amantadin-ratiopharm
Amantadinum
Amanta-hci-azu
AmantaHCIAZU
Amantasulfateazu
Amanta-sulfate-azu
Amantidine
Aminoadamantane
Amixx
AZU, amantadin
Azupharma brand OF amantadine hydrochloride
Azupharma brand OF amantadine sulfate
Cerebramed
Ciba geigy brand OF amantadine hydrochloride
Ciba-geigy brand OF amantadine hydrochloride
Desitin brand OF amantadine hydrochloride
Du pont brand OF amantadine hydrochloride
|
Endantadine
endo Brand OF amantadine hydrochloride
Gen amantadine
Gen-amantadine
GenAmantadine
Genpharm brand OF amantadine hydrochloride
Hexal brand OF amantadine sulfate
Hormosan brand OF amantadine sulfate
Hydrochloride, amantadine
Infecto flu
Infecto-flu
InfectoFlu
Infectopharm brand OF amantadine hydrochloride
Infex
Juventus brand OF amantadine hydrochloride
Juventus, amantadina
Krewel brand OF amantadine hydrochloride
Llorente brand OF amantadine hydrochloride
Llorente, amantadina
Mantadine
Mantadix
Merz brand OF amantadine sulfate
Midantan
Neuraxpharm brand OF amantadine sulfate
Neuro hexal brand OF amantadine sulfate
Novartis brand OF amantadine hydrochloride
NSC-341865
Orion brand OF amantadine hydrochloride
Pharmascience brand OF amantadine hydrochloride
Pk-Merz
PMS Amantadine
PMSAmantadine
PMS-Amantadine
Ratiopharm brand OF amantadine hydrochloride
Solvay brand OF amantadine hydrochloride
Stada brand OF amantadine hydrochloride
Stada brand OF amantadine sulfate
Stada, amantadin
Sulfate, amantadine
Symadine
Symmetrel
TCMDC-125869
Thiemann brand OF amantadine hydrochloride
Tregor
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Viregyt
Virosol
Wiregyt
|
|
6 |
|
Zoledronic acid |
Approved |
Phase 4 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
7 |
|
Iodine |
Approved, Investigational |
Phase 4 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
8 |
|
Zonisamide |
Approved, Investigational |
Phase 4 |
|
68291-97-4 |
5734 |
Synonyms:
1,2-Benzisoxazole-3-methanesulfonamide
1,2-Benzisoxazole-3-methanesulphonamide
3 Sulfamoylmethyl 1,2 benzisoxazole
3-(Sulfamoylmethyl)-1,2-benzisoxazole
3-(Sulphamoylmethyl)-1,2-benzisoxazole
3-Sulfamoylmethyl-1,2-benzisoxazole
AD-810
AD-810|CI-912|PD-110843|Zonegran®
Benzo[D]isoxazol-3-yl-methanesulfonamide
Benzo[D]isoxazol-3-yl-methanesulphonamide
CI-912
Elan brand OF zonisamide
|
Exceglan
Excegram
Excegran
PD-110843
Zonegran
Zonisamida
Zonisamida [Spanish]
Zonisamide
Zonisamide monosodium
Zonisamidum
Zonisamidum [Latin]
|
|
9 |
|
Droxidopa |
Approved, Investigational |
Phase 4 |
|
23651-95-8 |
443940 92974 |
Synonyms:
(-)-(2S,3R)-2-AMINO-3-HYDROXY-3-(3,4-DIHYDROXYPHENYL)PROPANOIC ACID
(2R,3S)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate
(2S,3R)-3,4-DIHYDROXY-PHENYLSERINE
3,4 Dihydroxyphenylserine
3,4 Threo dops
3,4-Dihydroxyphenylserine
3,4-Threo-dops
DL Threo 3,4 dihydroxyphenylserine
DL-Threo-3,4-dihydroxyphenylserine
Dops
Droxidopa
Droxidopa, (DL-tyr)-isomer
Droxydopa
Erythro 3,4 dihydroxyphenylserine
|
Erythro-3,4-dihydroxyphenylserine
L-Dihydroxyphenylserine
L-DOPS
L-DOPS|Northera®|SM-5688
L-Threo-3,4-dihydroxyphenylserine
L-threo-dihydroxyphenylserine
L-THREODOPS
Northera
SM 5688
SM-5688
Threo dops
THREO-DOPASERINE
Threo-dops
|
|
10 |
|
Cadexomer iodine |
Experimental |
Phase 4 |
|
94820-09-4 |
|
Synonyms:
|
11 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
12 |
|
Nicotinic Agonists |
|
Phase 4 |
|
|
|
13 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
14 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
15 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
16 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
17 |
|
Antipsychotic Agents |
|
Phase 4 |
|
|
|
18 |
|
Quetiapine Fumarate |
|
Phase 4 |
|
111974-72-2 |
|
Synonyms:
ICI-204636
QUETIAPINE FUMARATE
SEROQUEL
|
SEROQUEL XR
ZD-5077
ZM-204636
|
|
19 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
20 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
21 |
|
Dopamine Antagonists |
|
Phase 4 |
|
|
|
22 |
|
Antiemetics |
|
Phase 4 |
|
|
|
23 |
|
Serotonin Uptake Inhibitors |
|
Phase 4 |
|
|
|
24 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
25 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
26 |
|
Analgesics |
|
Phase 4 |
|
|
|
27 |
|
Radiopharmaceuticals |
|
Phase 4 |
|
|
|
28 |
|
3-Iodobenzylguanidine |
|
Phase 4 |
|
|
|
29 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
30 |
|
Hormones |
|
Phase 4 |
|
|
|
31 |
|
Anticonvulsants |
|
Phase 4 |
|
|
|
32 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
33 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
34 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
35 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
36 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
37 |
|
Carbon monoxide |
Approved, Investigational |
Phase 3 |
|
630-08-0 |
281 |
Synonyms:
[CO]
C#O
Carbon monoxide
carbon(II) oxide
|
Carboneum oxygenisatum
CO
Monoxide, carbon
|
|
38 |
|
Dopamine agonists |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Levodopa |
Approved |
Phase 2 |
|
59-92-7, 63-84-3 |
6047 |
Synonyms:
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(−)-3-(3,4-DIHYDROXYPHENYL)-L-ALANINE
(-)-Dopa
(−)-DOPA
(+-)-3-(3,4-Dihydroxyphenyl)alanine
(+-)-Dopa
(+/-) 3-(3,4-dihydroxyphenyl)alanine
(2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
(R,S)-Dopa
2-amino-3-(3,4-Dihydroxyphenyl)propanoate
2-amino-3-(3,4-Dihydroxyphenyl)propanoic acid
3 Hydroxy DL tyrosine
3 Hydroxy L tyrosine
3-(3,4-Dihydroxyphenyl)-DL-alanine
3-(3,4-Dihydroxyphenyl)-L-alanine
3,4 Dihydroxyphenylalanine
3,4-Dihydroxy-DL-phenylalanine
3,4-Dihydroxy-L-phenylalanine
3,4-dihydroxy-L-phenylalanine|Inbrija® (levodopa inhalation powder)|L-DOPA|Sinemet®
3,4-Dihydroxyphenylalanine
3',4'-Dihydroxyphenylalanine
3,4-Dihydroxyphenyl-L-alanine
3-Hydroxy-DL-tyrosine
3-Hydroxy-L-tyrosine
3-Hydroxytyrosine
a-amino-3,4-Dihydroxy-benzenepropanoate
a-amino-3,4-Dihydroxy-benzenepropanoic acid
alpha-amino-3,4-Dihydroxy-benzenepropanoate
alpha-amino-3,4-Dihydroxy-benzenepropanoic acid
alpha-amino-Hydrocaffeic acid
b-(3,4-Dihydroxyphenyl)-a-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
b-(3,4-Dihydroxyphenyl)-DL-a-alanine
b-(3,4-Dihydroxyphenyl)-L-alanine
Bendopa
beta Hydroxytyrosine
beta-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-DL-alpha-alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-Hydroxytyrosine
BROCADOPA
Cidandopa
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
Dihydroxyphenylalanine hydrochloride, (2:1)
DL-3,4-Dihydroxyphenylalanine
DL-3',4'-Dihydroxyphenylalanine
DL-3,4-Dopa
DL-3-Hydroxytyrosine
DL-4,5-Dihydroxyphenylalanine
DL-b-(3,4-Dihydroxyphenyl)-a-alanine
DL-b-(3,4-Dihydroxyphenyl)alanine
DL-beta-(3,4-Dihydroxyphenyl)alanine
DL-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
DL-Dihydroxyphenylalanine
DL-Dioxyphenylalanine
|
DL-Î’-(3,4-dihydroxyphenyl)alanine
DL-Β-(3,4-dihydroxyphenyl)-α-alanine
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopalina
Dopar
Doparkine
Doparl
Dopasol
Dopaston
Dopastone
Dopastral
Dopicar
Doprin
Eldopal
Eldopar
Eldopatec
Eurodopa
Helfo-dopa
INBRIJA
Insulamina
L 3,4 Dihydroxyphenylalanine
L Dopa
L-(-)-Dopa
L-3-(3,4-Dihydroxyphenyl)-alanine
L-3,4-Dihydroxyphenylalanine
L-4-5-Dihydroxyphenylalanine
Laradopa
Larodopa
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-b-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-Dihydroxyphenylalanine
L-DOPA
LDP540
Ledopa
Levedopa
Levodopa
Levodopum
Levopa
L-Î’-(3,4-dihydroxyphenyl)alanine
Maipedopa
Medphano brand OF levodopa
NSC-118381
Parda
Pardopa
Prodopa
Roberts brand OF levodopa
Roche brand OF levodopa
SINEMET
Syndopa
V-1512
Veldopa
Weldopa
Î’-(3,4-dihydroxyphenyl)alanine
Β-(3,4-dihydroxyphenyl)-DL-α-alanine
Î’-(3,4-dihydroxyphenyl)-L-alanine
|
|
40 |
|
Clonazepam |
Approved, Illicit |
Phase 2 |
|
1622-61-3 |
2802 |
Synonyms:
1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one
5-(2-Chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one
5-(O-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Antelepsin
Chlonazepam
CLONAZEPAM
CLONAZEPAM CIV
Clonazepam fine granules
Clonazepam tablets
|
Clonazepamum
Klonopin
KLONOPIN RAPIDLY DISINTEGRATING
Klonopin®|Ro-5-4023|Ro-54023
NSC-179913
Rivotril
RO-54023
RO-5-4023
RO-5423
|
|
41 |
|
Pramipexole |
Approved, Investigational |
Phase 2 |
|
104632-26-0, 104632-25-9, 104632-28-2 |
4885 119570 59868 |
Synonyms:
(-)-Pramipexole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
2 Amino 6 propylaminotetrahydrobenzothiazole
2,6-BENZOTHIAZOLEDIAMINE, 4,5,6,7-TETRAHYDRO-N(SUP 6)-PROPYL-, (S)-
2-Amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-Amino-6-propylaminotetrahydrobenzothiazole
4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazole-diamine
6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate
Dexpramipexole
Furfuryl Acetate
Mirapex
MIRAPEX ER
MIRAPEX EXTENDED RELEASE
Mirapex®|Mirapexin®|Sifrol®|SND-919CL2Y|U-98528E
MIRAPEXIN
NELIPRAX
OPRYMEA
PIPEXUS
Pramipexol
Pramipexol [Spanish]
Pramipexol dihydrobromide, (+-)-isomer
|
Pramipexol dihydrochloride, (S)-isomer
Pramipexol, (+-)-isomer
Pramipexol, (R)-isomer
Pramipexole
Pramipexole 2HCl Monohydrate
Pramipexole dihydrochloride
Pramipexole dihydrochloride anhydrous
Pramipexole hydrochloride
Pramipexole hydrochloride monohydrate
Pramipexolum
Pramipexolum [Latin]
Sifrol
Sifrole
SND 919
SND 919CL2X
SND-919
SND919CL2X
SND-919CL2X
SND-919CL2Y
SUD-919CL2Y
U-98528E
|
|
42 |
|
Licorice |
Approved |
Phase 1, Phase 2 |
|
|
|
Synonyms:
|
43 |
|
Turmeric |
Approved, Experimental, Investigational |
Phase 1, Phase 2 |
|
|
|
Synonyms:
Ae-turmeric
Allergenic Extract- Turmeric Curcuma Longa
Amomum Curcuma Root
Constrained Metal (Curcuma Longa)
Curcuma Brog Root
Curcuma Domestica Extract
Curcuma Domestica Root
Curcuma Euchroma Root
Curcuma Longa
Curcuma Longa (Turmeric) Rhizome Extract
Curcuma Longa (Turmeric) Root
Curcuma Longa (Turmeric) Root Extract
Curcuma Longa (Turmeric) Root Powder
Curcuma Longa Extract
Curcuma Longa Rhizome
Curcuma Longa Rhizome Extract
Curcuma Longa Root
Curcuma Longa Root Dry Extract
Curcuma Longa Root Extract
Curcuma Longa Root Tuber
Curcuma Montana Root
Curcuma Ochrorhiza Root
Curcuma Soloensis Root
Curcuma Viridiflora Root
Curcumae Longae Rhizoma
Curcumae Longae Rhizoma (Cucuma Longa)
Curcumae Longae Rhizoma (Curcuma Longa)
Curcumae Radix (Curcuma Longa)
|
Curcumae Rhizoma (Curcuma Longa)
Curcumarum Tuber Et Radix (Curcuma Longa)
Ginger Yellow (Curcuma Longa)
Guiyujin (Curcuma Longa)
Haldi Root
Haridra Root
Huangsiyujin (Cucuma Longa)
Indian Saffron Root
Jiang Huang (Curcuma Longa)
Jianghuang
Kua Domestica Root
Lusiyujin (Curcuma Longa)
Spices, Turmeric, Ground
Stissera Curcuma Root
Stissera Longa Root
Turmeric Extract
Turmeric Rhizome (Curcuma Longa)
Turmeric Root
Turmeric Root Extract
Turmeric Root Powder
Turmeric Root Tuber (Curcuma Longa)
Turmeric Tuber (Curcuma Longa)
Turmeric,ground
Wunyujin (Cucuma Longa)
Yellow Ginger Root
Yu Jin
Yujin (Curcuma Longa)
|
|
44 |
|
Ethanol |
Approved |
Phase 2 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
45 |
|
Fluorodeoxyglucose F18 |
|
Phase 2 |
|
|
|
46 |
|
GABA Modulators |
|
Phase 2 |
|
|
|
47 |
|
Fluorides |
|
Phase 2 |
|
|
|
48 |
|
Antioxidants |
|
Phase 2 |
|
|
|
49 |
|
Protective Agents |
|
Phase 2 |
|
|
|
50 |
|
2beta-carbomethoxy-3beta-(4-iodophenyl)tropane |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 130)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response |
Unknown status |
NCT03495024 |
Phase 4 |
Varenicline |
2 |
A Multicentre, Randomised, Open Label, Comparative Phase 4 Trial to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism in a General Neurologist Setting. |
Completed |
NCT00382967 |
Phase 4 |
|
3 |
Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) |
Completed |
NCT00043849 |
Phase 4 |
Quetiapine |
4 |
A Randomized Controlled Trial Study of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism |
Completed |
NCT00331825 |
Phase 4 |
Risperidone and Olanzapine |
5 |
The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia |
Completed |
NCT00950196 |
Phase 4 |
amantadine sulphate |
6 |
TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease |
Recruiting |
NCT03924414 |
Phase 4 |
Zoledronic Acid 5Mg/Bag 100Ml Inj |
7 |
Myocardial 123I-MIBG Scintigraphy in Aging and Neurodegenerative Disease |
Enrolling by invitation |
NCT05514106 |
Phase 4 |
meta-iodobenzylguanidine (MIBG) (123I) |
8 |
DaTSCAN Imaging in Aging and Neurodegenerative Disease |
Enrolling by invitation |
NCT01453127 |
Phase 4 |
I-123 Ioflupane solution injection prior to SPECT scan (DaTscan) |
9 |
An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease |
Suspended |
NCT03034538 |
Phase 4 |
Zonegran |
10 |
A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease |
Terminated |
NCT03034564 |
Phase 4 |
Northera;Placebo Oral Tablet |
11 |
Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication |
Unknown status |
NCT02138864 |
Phase 3 |
|
12 |
An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis |
Completed |
NCT01550484 |
Phase 2, Phase 3 |
18F-AV-133 |
13 |
A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCANâ„¢ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls |
Completed |
NCT04193527 |
Phase 3 |
DaTSCANâ„¢ Ioflupane (123I) Injection |
14 |
Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease |
Unknown status |
NCT01860794 |
Phase 1, Phase 2 |
Mesencephalic Neuronal Precursor Cells |
15 |
Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET |
Completed |
NCT02059733 |
Phase 2 |
18F-DTBZ |
16 |
Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism: a Prospective, Randomized, Double-blind and Placebo-controlled Trial |
Completed |
NCT02312908 |
Phase 2 |
Clonazepam;Placebo |
17 |
Novel Neuroimage Study in Tauopathies With Parkinsonism |
Completed |
NCT03386669 |
Phase 2 |
F-18 |
18 |
Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism |
Completed |
NCT00132626 |
Phase 2 |
[123I]ß-CIT and SPECT imaging |
19 |
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism |
Completed |
NCT01653132 |
Phase 2 |
Incobotulinum Toxin A;Placebo |
20 |
From Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism |
Completed |
NCT01759888 |
Phase 2 |
18F-DTBZ |
21 |
18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism: Investigating the Correlation Between Cerebral Structural and Functional Changes, and Clinical Manifestation |
Completed |
NCT02195154 |
Phase 2 |
18F-DTBZ |
22 |
The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ) |
Completed |
NCT01824056 |
Phase 2 |
18F-FDG |
23 |
Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome |
Completed |
NCT00117819 |
Phase 2 |
[123I]ß CIT and SPECT imaging |
24 |
Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's |
Completed |
NCT00096720 |
Phase 2 |
levodopa;Mirapex (pramipexole) |
25 |
Development of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's Symptoms |
Completed |
NCT00129675 |
Phase 2 |
[123I]ß CIT |
26 |
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease |
Completed |
NCT00315250 |
Phase 2 |
[123I]β-CIT |
27 |
Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression. |
Completed |
NCT00273351 |
Phase 2 |
[123I]B-CIT |
28 |
Treating Sequalae Caused by Post-acute Sequelae of SARS (Severe Acute Respiratory Syndrome)-CoV-2 Infection |
Recruiting |
NCT04846010 |
Phase 1, Phase 2 |
|
29 |
Efficacy and Safety of Astragalus for Non-Motor Symptoms of Parkinsonism:an Open-Label Self-Controlled Before-and-After Study |
Recruiting |
NCT05506891 |
Phase 2 |
Astragalus |
30 |
Effect of Exercise on Recovery in Drug-Induced Parkinsonism and Parkinson Disease |
Active, not recruiting |
NCT02598973 |
Phase 1, Phase 2 |
|
31 |
Does Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism? |
Withdrawn |
NCT00472355 |
Phase 2 |
apomorphine |
32 |
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) |
Withdrawn |
NCT01565395 |
Phase 2 |
Incobotulinum Toxin A;placebo |
33 |
Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism |
Withdrawn |
NCT03446807 |
Phase 2 |
Droxidopa;Placebo Oral Tablet |
34 |
Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients |
Unknown status |
NCT00767546 |
Phase 1 |
Botulinum toxin |
35 |
Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients |
Completed |
NCT00845000 |
Phase 1 |
SCH 420814 10 mg;SCH 420814 100 mg;Placebo;Levodopa;Carbidopa |
36 |
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies |
Completed |
NCT01056965 |
Phase 1 |
davunetide (AL-108, NAP);Placebo nasal spray |
37 |
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease |
Active, not recruiting |
NCT04075318 |
Phase 1 |
|
38 |
BEWARE: Body Awareness Training in the trEatment of Wearing-off Related Anxiety in Patients With paRkinson's diseasE. |
Unknown status |
NCT02054845 |
|
|
39 |
Clinical, Molecular and by Neuroimaging Characterization of Monogenic Forms of Parkinsonism Syndromes: Mutations of the LRRK2 Gene. |
Unknown status |
NCT01085227 |
|
|
40 |
Imaging Neuromelanin and Iron in Dystonia/Parkinsonism |
Unknown status |
NCT03572114 |
|
|
41 |
Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism |
Unknown status |
NCT02361255 |
|
|
42 |
Understanding Autonomic Function in REM Sleep Behavior Disorder, Parkinsonism and Controls |
Unknown status |
NCT01674998 |
|
|
43 |
Observational Study Assessing the Diagnostic Contribution of 3-Tesla MRI, CSF Analysis and a Second Opinion in a Specialized Movement Disorder Centre, in Differentiating Between Parkinson's Disease and Atypical Parkinsonism |
Unknown status |
NCT01249768 |
|
|
44 |
LIPAD - LRRK2 International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study |
Unknown status |
NCT04214509 |
|
|
45 |
Thoracic Dorsal Spinal Cord Stimulation for the Treatment of Gait and Balance Impairments in Parkinson Disease |
Unknown status |
NCT03079310 |
|
|
46 |
The Efficacy of Long-term Whole-body Vibration in the Treatment of Parkinson's Disease |
Unknown status |
NCT02306863 |
|
|
47 |
Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease:a Double Blind Cross-over Sham-controlled Study Using Wearing Sensors Technology |
Unknown status |
NCT04238000 |
|
|
48 |
Systems Medicine of Mitochondrial and Biochemical Parkinson's Disease and Other Related Movement Disorders |
Unknown status |
NCT03421899 |
|
|
49 |
Effects of Motor Imagery and Action Observation Training on Gait and Brain Activation Pattern of Individuals With Parkinson's Disease: Randomized Controlled Clinical Trial |
Unknown status |
NCT03439800 |
|
|
50 |
Improving Posture in Parkinson's Patients Through Home-based Training and Biofeedback |
Unknown status |
NCT03477695 |
|
|
|